What is SLU-PP-332 Peptide
SLU-PP-332 is a synthetic small molecule developed at Saint Louis University School of Medicine that acts as a selective estrogen related receptor alpha (ERRα) agonist. This research peptide is an exercise mimetic that delivers metabolic benefits of aerobic exercise without exercise. Unlike other peptides, SLU-PP-332 is orally available with high bioavailability and stability.
The compound targets estrogen related receptors, specifically ERRα which is critical for whole body metabolism, mitochondrial function and energy expenditure. Research shows SLU-PP-332 increases exercise capacity, improves insulin sensitivity and fatty acid oxidation in skeletal muscle and other metabolically active tissues. It’s a promising candidate for metabolic syndrome, diet induced obesity and various chronic diseases related to mitochondrial dysfunction.
Current studies are focusing on SLU-PP-332’s ability to increase mitochondrial respiration, energy expenditure and metabolic health markers in animal models. It mimics exercise by activating the same cellular pathways involved in endurance training adaptations making it very useful for populations that cannot exercise regularly. As an investigational compound, SLU-PP-332 should be used under proper research protocols and physician supervision.
Molecular Structure and Chemical Data
SLU-PP-332, also known as 4-hydroxy-N’-(2-naphthylmethylene)benzohydrazide, has the CAS number 303760-60-3 and is a novel class of synthetic ERR agonists. This synthetic errα compound is a white to off-white crystalline solid with a density of 1.20 g/cm³. The molecular structure allows high affinity binding to estrogen related receptor alpha without estrogenic side effects.
For research use only, 99%+ purity is required and verified through NMR and HPLC testing. It’s soluble in DMSO up to 2mg/mL with a predicted pKa of 8.44. Storage should be at 2-8°C to maintain molecular integrity and prevent degradation.Handling protocols should be followed for proper storage and measurement. The compound is stable for extended research use when stored properly, making it suitable for long term metabolic studies and cellular research on mitochondrial biogenesis and energy metabolism pathways.
Research Areas for SLU-PP-332 Peptide
SLU-PP-332 research is focused on exercise mimetics and metabolic health. Studies in obese mice show significant weight loss, increased fat oxidation and reversal of hepatic steatosis. The compound increases energy expenditure without changing food intake making it very useful for diet induced obesity and metabolic syndrome research.
Cardiovascular research is looking into SLU-PP-332’s effect on cardiac fatty acid metabolism and heart failure models, especially HFpEF (heart failure with preserved ejection fraction) and HFrEF (heart failure with reduced ejection fraction). Animal models show improved exercise endurance and increased mitochondrial respiration in cardiac tissue, suggesting cardioprotective effects through optimized cellular energy production.
Skeletal muscle cell lines provide insights into SLU-PP-332’s mechanism in promoting mitochondrial biogenesis and cellular repair. Research shows increased expression of genes involved in fatty acid oxidation, improved insulin sensitivity and increased exercise capacity. This is useful for aging research where mitochondrial dysfunction contributes to age related decline in muscle function and overall metabolic health.
Other research areas include neurodegenerative diseases, chronic fatigue conditions and inflammatory disorders. The compound reduces pro inflammatory cytokines and increases mitochondrial respiration making it a potential therapeutic for conditions characterized by cellular energy deficits.
Mechanism Of Action For SLU-PP-332 Peptide
SLU-PP-332 binds to estrogen related receptor alpha with high affinity (EC50 98 nM) and triggers a cascade of metabolic adaptations that increase mitochondrial function and energy metabolism. Upon receptor activation, the compound upregulates PGC-1α, the master regulator of mitochondrial biogenesis, resulting in increased mitochondrial density and improved cellular respiration capacity. Activation of estrogen related receptors by SLU-PP-332 triggers the transcription of hundreds of exercise related genes including GLUT4 transporters and uncoupling proteins (UCPs) that facilitate glucose uptake and thermogenesis. This genetic response shifts the metabolism from glucose dependence to fatty acid utilization as seen by decreased respiratory exchange ratios in treated subjects.
At the cellular level, SLU-PP-332 increases fatty acid oxidation enzymes in skeletal muscle, adipose tissue and cardiac muscle, improves lipid metabolism and reduces insulin resistance. The compound stimulates autophagy and mitophagy, the process of removing damaged cellular components and promoting tissue repair mechanisms necessary for metabolic health.
Research shows SLU-PP-332’s effects on whole body metabolism go beyond caloric expenditure, involving complex interactions between liver, muscle and white adipose tissue that together improve body composition and reduce markers of metabolic diseases. This comprehensive metabolic reprogramming makes it an effective exercise mimetic.
Future Research Directions For SLU-PP-332 Peptide
Clinical research priorities for SLU-PP-332 are to establish human safety profiles and optimal dosing protocols. Preclinical data suggests effective range of 0.25mg to 1.5mg administered 1-3 times daily. Future studies need to address long term effects of chronic ERR activation and potential side effects that may emerge with extended use in human populations.
Combination therapy research is a promising area, investigating SLU-PP-332’s synergy with other metabolic interventions, lifestyle modifications and existing treatments for metabolic syndrome. Studies on interaction with aerobic training protocols will optimize exercise mimetic benefits while maintaining the benefits of increased physical activity for overall human health.
Regulatory development requires comprehensive toxicology studies, pharmacokinetic profiling and dose-escalation trials to support FDA approval pathways. Comparison studies with other novel pan ERR agonists and established exercise mimetics will position SLU-PP-332 in the landscape of experimental therapeutics for metabolic diseases.
Aging research and neurodegenerative conditions are expanding frontiers, particularly investigating SLU-PP-332’s potential to address mitochondrial dysfunction associated with cognitive decline and age related tissue damage. Future studies need to examine the compound’s effect on inflammation, cellular repair mechanisms and its role as a key regulator of healthy aging.
Buy SLU-PP-332 Peptide at Loti Labs
Research grade SLU-PP-332 is available for qualified research institutions for exercise mimetics and metabolic health research. Quality control protocols ensure each batch meets high purity standards, with testing certificates documenting molecular integrity and 99%+ purity for reliable research results.
Standard packaging is 5-gram with 100mg measuring scoops for rodent models and cellular research. Storage guidelines are included with each shipment, refrigeration requirements and handling protocols to maintain compound stability during extended research periods.
Licensing requires institutional oversight and adherence to investigational use protocols for novel synthetic compounds. Customer support provides technical assistance for research applications to help investigators design experiments and comply with regulations for experimental therapeutics research.
Research must demonstrate legitimate scientific objectives and IRB approval for SLU-PP-332 studies. The compound is an investigational agent and requires documentation and adherence to protocols for handling experimental compounds in research settings.
Summary
SLU-PP-332 is an oral exercise mimetic that delivers metabolic benefits through selective estrogen related receptor α activation. Preclinical data shows significant improvements in mitochondrial function, exercise capacity, insulin sensitivity and weight loss in animal models, making it a new drug class for metabolic syndrome and related chronic diseases.
Studies by Billon et al. (2023), Xu et al. (2023) and Wang et al. (2023) demonstrate SLU-PP-332’s effects on whole body metabolism, fatty acid oxidation and mitochondrial biogenesis. Animal studies show no toxicity concerns, safe profile for human clinical trials under medical supervision.
The compound is investigational and more research is needed to establish therapeutic applications and long term safety in humans. Future studies will determine SLU-PP-332’s role in metabolic diseases, healthy aging and therapeutic options for people who cannot exercise.
As research continues, SLU-PP-332 becomes a promising candidate for metabolic health interventions, a solution for the global burden of obesity, diabetes and age related metabolic dysfunction through exercise mimetic approaches.
References
- Billon C, et al. (2023). ERR agonists enhance mitochondrial function in skeletal muscle. ACS Chem Biol.* Xu L, et al. (2023). SLU-PP-332 in diet-induced obesity. J Metabolic Research.
- Wang K, et al. (2023). Exercise mimetic effects of ERR agonists in cardiac fatty acid metabolism. Cardiovascular Research.
- Saint Louis University School of Medicine. (2023). Design and synthesis of ERR modulators.
